TuHURA BIOSCIENCES, INC./NV Preferred Stock Dividends, Income Statement Impact
TuHURA BIOSCIENCES, INC./NV (HURA) reported Preferred Stock Dividends, Income Statement Impact of -$209.81 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2017-05-12
- TuHURA BIOSCIENCES, INC./NV preferred stock dividends, income statement impact for the quarter ending 2017-03-31 was -$209.81K.
- TuHURA BIOSCIENCES, INC./NV preferred stock dividends, income statement impact for the quarter ending 2016-12-31 was $159.76K.
- TuHURA BIOSCIENCES, INC./NV preferred stock dividends, income statement impact for the quarter ending 2016-09-30 was $307.30K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month |
|---|---|---|---|
| 2017-03-31 | -$209.81K 10-Q · filed 2017-05-12 | -$50.05K derived: sum of 2 quarters · filed 2017-05-12 | -$676.87K 10-Q · filed 2017-05-12 |
| 2016-12-31 | $159.76K 10-Q · filed 2017-02-10 | $467.05K 10-Q · filed 2017-02-10 | |
| 2016-09-30 | $307.30K 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |